Wall Street Isn't Talking About High-Yield Medtronic Stock -- Here's Why It Should Be

Medtronic, a massive medical device manufacturer, has been attracting less attention from Wall Street despite its impressive growth and high dividend yield. One reason for this may be the company's size, which has led to bureaucratic inefficiencies and a bloated product lineup. However, recent strategic moves by Medtronic, such as divesting underperforming divisions and launching innovative technologies like its Hugo surgical robot, have reignited growth.

These changes have resulted in a decade-high revenue increase and above expectations earnings in the most recent quarter. The company's commitment to cutting-edge medical technology, coupled with its well-above-market dividend, makes Medtronic a compelling option for investors seeking stability and potential gains. Although Medtronic's stock has risen 15% in the past three months, it is still trading 30% below its 2021 peak, offering ample opportunities for further appreciation.

Despite being overlooked by some analysts, Medtronic could be a worthy addition to a diversified investment portfolio.